Immune treatment cured my terminal breast cancer

Phyllis Laccetti a participant in the TailorX breast cancer study at her home in Ossining NY

Phyllis Laccetti a participant in the TailorX breast cancer study at her home in Ossining NY

More than two years on, she is cancer-free and says she has "gone back to normal everyday life", even enjoying strenuous hiking and kayaking trips. First, this is a study of just one form of breast cancer and the authors found that chemo could still benefit some patients with the cancer - mainly younger women, regardless of their tumor's genetic "score".

Well, a groundbreaking new study says that doesn't need to be the case.

An experimental therapy that extracts and multiplies powerful immune-system cells from inside tumors eradicated a patient's breast cancer, a scientific first that could lead to new ways of treating malignancies that have resisted all other efforts. I also, then, lost my hair.

Angela Harris, head of Scotland at Breast Cancer Care, said: "This incredible news is game-changing as it means thousands of women in Scotland and across the United Kingdom will be able to avoid chemotherapy with confidence".

Previous research has shown that women with a low Oncotype Dx recurrence score (less than 10) are likely to respond to hormone therapy alone, whereas those with a score above 26 benefit from having a combination of chemotherapy and hormone therapy.

"Part of the excitement is because all cancers contain mutations, it's a technique that could potentially be applied to any tumor type", Rosenberg said.

This would mean those women can be spared chemotherapy, and its associated side effects, after surgery.

That's why it's great news to hear that doctors in the USA have just made an awesome scientific breakthrough through, curing a woman who was in the advanced stages of the disease. The patient's cancer could not have spread to the lymph nodes.

Research has shown that Oncotype Dx and other tests, including Breast Cancer Index and EndoPredict, vary in accuracy, particularly when predicting the long-term risk of someone's cancer coming back.

Jordanian PM Mulki Submits Resignation Amid Ongoing Protests
Two government-linked websites, Hala Akhbar and Al-Rai, reported on Monday (local time) that Mr Mulki had offered his resignation. King Abdullah on Saturday called on parliament to lead a "comprehensive and reasonable national dialogue" on the new tax law.

About 40,920 women in the US are expected to die in 2018 from breast cancer, though death rates have been decreasing since 1989. This is being called the largest breast cancer treatment trial ever conducted.

Mitchell said we now have a huge new population of patients who no longer need to go through all the side effects that come along with chemo.

Across the European Union, we have seen positive results for breast cancer care as more women are being diagnosed and treated earlier, leading to higher survival rates.

A patient's tumour is genetically analysed to identify the rare changes that might make the cancer visible to the immune system. The tumour is assigned a "recurrence score" from 0 to 100 - higher the score, greater the chance the cancer will recur, with chemotherapy reducing the risk of recurrence. Other patients may change their treatment approach based on the results.

Albain is excited to share the study results with her clients in her practice. Key secondary end points included freedom from recurrence of breast cancer at a distant site, freedom from recurrence of breast cancer at a distant or local-regional site, and overall survival (OS).

"I will explain that's why research is so important in helping us move forward in breast cancer care that's how we will achieve a cure for breast cancer", Figueredo said.

"We are now leaving an era where the only choice for non-small-cell lung cancer patients was to start with chemotherapy", he told reporters at the ASCO conference.

The success of this case has raised hopes that the therapy could also be used to treat advanced ovarian and prostate cancers.

Latest News